<DOC>
	<DOCNO>NCT02635971</DOCNO>
	<brief_summary>This study aim explore efficacy safety intra- arterial infusion gemcitabine oxaliplatin locally advanced pancreatic cancer . This protocol overseen Fudan University Institutional Review Board Federal Wide Assurance U.S. Department Health &amp; Human Services ( Approved : April 25 , 2002 ) .</brief_summary>
	<brief_title>Intra-arterial Versus Intravenous Chemotherapy Locally Advanced Pancreatic Cancer</brief_title>
	<detailed_description>Primary Outcome Measures : To compare overall survival ( OS ) patient locally advanced pancreatic cancer treat transcatheter arterial infusion ( TAI ) chemotherapeutics systemic deliver chemotherapy . Secondary Outcome Measures : To compare progression free survival ( PFS ) , objective response rate ( ORR ) , quality life ( QoL ) , adverse effect treat locally advanced pancreatic cancer patient TAI systemic chemotherapy . Exploratory Outcome Measures : To evaluate correlation prognosis expression serum microRNAs patient .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Histologically/cytologically confirm unresectable locally advanced pancreatic adenocarcinoma . Measurable disease RECIST criterion must present . Karnofsky Performance Status ≥ 70 Patients adequate organ function reflect laboratory criterion : Granulocytes ≥ 1,500/uL Hemoglobin ≥ 8.0 gm/dL Platelets ≥ 100,000/uL Serum creatinine &lt; 2.0 mg/dL Bilirubin &lt; 1.5 mg/dL SGPT &lt; 2.5 x normal Alk Phos &lt; 2.5 x normal Prior local therapy , e.g. , radiation , allow provide least 4 week washout time give . Patients jaundice must biliary drainage decompression operation recruitment . Patients must pregnant . Serum betaHCG check premenopausal patient . Ability understand willingness sign write informed consent . Subject metastatic disease . Prior treatment systemic chemotherapy . Known allergy gemcitabine , oxaliplatin iodine contrast agent . Subject ChildPugh grade Class C hepatic impairment , active gastrointestinal bleeding , severe coagulation disorder could corrected，or contraindication transcatheter infusion . Untreated uncontrolled deep vein thrombosis , arterial thrombosis lower extremity , aneurysm . Concurrent infection require intravenous antibiotic . Skin injury infection groin area , situation appropriate femoral artery puncture . Other serious illness condition include cardiac disease include congestive heart failure ( New York Heart Association Classification III IV ) , active HIV infection/HIV disease , psychiatric disorder . Known central nervous system involvement leptomeningeal disease Subject previous concurrent cancer distinct primary site histology pancreatic adenocarcinoma except cervical carcinoma situ , nonmelanoma carcinoma skin situ carcinoma bladder . Any cancer curatively treat great 3 year prior entry permit . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>transcatheter arterial infusion</keyword>
	<keyword>randomize control trial</keyword>
	<keyword>chemotherapy</keyword>
</DOC>